Ortho Clinical Diagnostics and Thermo Fisher Scientific Agree to Deliver 14 Assays for Use on Ortho's VITROS® Systems

Published: Apr 05, 2018

RARITAN, N.J., April 5, 2018 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced an international distribution and co-promotion agreement with Thermo Fisher Scientific to provide 14 assays used to monitor therapeutic drugs, immunosuppressive drugs and drugs of abuse. The agreement is part of Ortho's ongoing MicroTip Partnership Assays program, through which Ortho collaborates with other diagnostics companies to validate and deliver a broad range of assays to the hospitals, hospital networks and labs who use Ortho's VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.

The immunosuppressive drugs tests covered by this agreement are used to monitor transplant patients to prevent over-suppression or organ rejection, while the therapeutic drug tests are used to confirm drug levels in the body and monitor compliance and toxicity. The testing menu for drugs of abuse is used to monitor both illicit and prescription drugs in cases of suspected abuse. It includes tests used to monitor and treat opioid addiction and those used to check levels of pain medication.

"This new agreement with Thermo Fisher Scientific will help us meet customer needs, now and into the future, helping health care professionals grapple with persistent and significant problems like opioid addiction and treatment," said Robert Yates, Ortho's chief operating officer. "Ortho is committed to its robust internal R&D programs, as well as collaborating with other innovative companies to expand its menu and bring greater medical value to our customers."

The assays will initially be launched in North America, Europe, Africa and the Middle East.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management, and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.

© Ortho Clinical Diagnostics 2018

PR-03725

 

CONTACT: Jane Ward, Ortho Clinical Diagnostics, Jane.ward@orthoclinicaldiagnostics.com, 908-210-0118

View original content with multimedia:http://www.prnewswire.com/news-releases/ortho-clinical-diagnostics-and-thermo-fisher-scientific-agree-to-deliver-14-assays-for-use-on-orthos-vitros-systems-300624989.html

SOURCE Ortho Clinical Diagnostics

     

Back to news